GenCore version 5.1.4_p5_4578

OM nucleic - nucleic search, using sw model

Run on: March 20, 2003, 01:47:25 ; Search time 237 Seconds
(without alignments)
5311.675 Million cell updates/sec

Title: US-09-867-958-2
Perfect score: 559
Sequence: 1 ccgcaatggcacggcagcac.....cgcctaggcctttgtcagcg 559

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 1125999159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_101002:*
1: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1980.DAT:*
2: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1981.DAT:*
3: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1982.DAT:*
4: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1983.DAT:*
5: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1984.DAT:*
6: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1985.DAT:*
7: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1986.DAT:*
8: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1987.DAT:*
9: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1988.DAT:*
10: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1989.DAT:*
11: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1990.DAT:*
12: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1991.DAT:*
13: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1992.DAT:*
14: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1993.DAT:*
15: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1994.DAT:*
16: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1995.DAT:*
17: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1996.DAT:*
18: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1997.DAT:*
19: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1998.DAT:*
20: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA1999.DAT:*
21: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2000.DAT:*
22: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001A.DAT:*
23: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2001B.DAT:*
24: /SIDS2/gcgdata/geneseq/geneseqn-embl/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

	Result No.	Score	% Query Match	Length	DB	ID	Description
	1	559	100.0	559	20	AAX36136	DNA encoding a hum
	2	549.4	98.3	1006	22	AAI58712	Human polynucleoti
	3	434.6	77.7	1859	22	AAK55488	Human immune/haema
	4	432.2	77.3	1869	22	AAI58813	Human polynucleoti
	5	381.8	68.3	1074	22	AAI60498	Human polynucleoti
	6	103	18.4	2007	24	ABQ54845	Human ovarian anti
	7	102.6	18.4	764	22	AAI97619	Human neuroblastom
	8	101.2	18.1	483	22	AAH43100	Nucleotide sequenc
	9	94.2	16.9	569	24	ABQ58935	Human colon cancer
	10	94.2	16.9	664	24	ABQ57521	Human colon cancer
	11	93	16.6	570	24	ABL37927	Human colon tumour
	12	84.4	15.1	575	24	ABQ59145	Human colon cancer
	13	82.6	14.8	561	24	ABQ58126	Human colon cancer
c	14	75.2	13.5	473	24	ABK09599	Human ovarian tumo
c	15	65.4	11.7	471	24	ABN88218	Human colon cancer
	16	56.6	10.1	1776	24	ABL39694	Human NS cDNA sequ
	17	54.4	9.7	314	22	AAF84993	Nucleic acid seque
	18	50.4	9.0	477	21	AAF21984	Human breast and o
	19	48.8	8.7	447	22	AAI82544	Human polynucleoti
	20	45.2	8.1	587	21	AAC06253	Human secreted pro
	21	39	7.0	441	23	ABV17722	Human prostate exp
	22	39	7.0	497	23	ABV47515	Human prostate exp
	23	38.2	6.8	2418	23	ABL03387	Drosophila melanog
	24	38.2	6.8	4204	23	ABL04694	Drosophila melanog
	25	38.2	6.8	4477	23	ABL03386	Drosophila melanog
	26	35.2	6.3	301	24	ABK93035	cDNA encoding huma
	27	35.2	6.3	3929	23	AAS70024	DNA encoding novel
	28	35.2	6.3	3933	16	AAT03885	Human mucosal lymp
c	29	34.6	6.2	467	22	ABA51936	Human foetal li...
c	30	34.6	6.2	467	22	ABA21751	Probe #217 for
c	31	34.6	6.2	467	22	AAK00225	Human brain exp...
c	32	34.6	6.2	467	22	AAK25668	Human bone marrow
c	33	34.6	6.2	467	22	AAI10295	Probe #228 for gen
c	34	34.6	6.2	467	22	AAI31544	Probe #230 used to
c	35	34.6	6.2	467	22	AAI00231	Probe #222 used to
c	36	34.6	6.2	467	24	ABS00240	Human genome-deriv
c	37	34.6	6.2	1186	22	ABA46719	Human breast cell
c	38	34.6	6.2	1186	22	ABA64595	Human foetal liver
c	39	34.6	6.2	1186	22	ABA31721	Probe #10187 for g
c	40	34.6	6.2	1186	22	AAK13036	Human brain expres
c	41	34.6	6.2	1186	22	AAK38767	Human bone marrow
c	42	34.6	6.2	1186	22	AAI19573	Probe #9506 for ge
c	43	34.6	6.2	1186	22	AAI44765	Probe #13451 used
c	44	34.6	6.2	1186	22	AAI05293	Probe #5284 used t
c	45	34.6	6.2	1186	24	ABS12841	Human genome-deriv

ALIGNMENTS

RESULT 1
AAX36136
ID AAX36136 standard; DNA; 559 BP.
XX
AC AAX36136;
XX
DT 19-JUL-1999 (first entry)
XX
DE DNA encoding a human progesterone receptor complex p23-like protein.
XX
KW Human progesterone receptor complex p23-like protein; PR23P;
KW neurological disorder; antagonist; reproductive disorder;
KW immunological disorder; neoplastic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO9919483-A1.
XX
PD 22-APR-1999.
XX
PF 09-OCT-1998; 98WO-US21402.
XX
PR 09-OCT-1997; 97US-0948197.
XX
PA (INCY-) INCYTE PHARM INC.
XX
PI Corley NC, Shah P, Yue H;
XX
DR WPI; 1999-302530/25.
DR P-PSDB; AAY02591.
XX
PT Human progesterone receptor complex p23-like protein

```
XX
PS   Claim 7; Fig 1A-B; 67pp; English.
XX
CC   The present sequence encodes a human progesterone receptor complex
CC   p23-like protein (PR23P). PR23P is used to treat neurological
CC   disorders. Antagonists of PR23P are useful for treating reproductive,
CC   immunological or neoplastic disorders. Probes and primers based on the
CC   PR23P polynucleotides can be used for diagnosis, detection and screening
CC   of homologues, and amplification of PR23P genes. Antisense PR23P
CC   polynucleotides can be used to decrease or inhibit expression of PR23P.
XX
SQ   Sequence 559 BP; 140 A; 114 C; 165 G; 140 T; 0 other;

  Query Match            100.0%;  Score 559;  DB 20;  Length 559;
  Best Local Similarity  100.0%;  Pred. No. 4.6e-171;
  Matches  559;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy      1 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCA 60
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db      1 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCA 60

Qy     61 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     61 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 120

Qy    121 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    121 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 180

Qy    181 AAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    181 AAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 240

Qy    241 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    241 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 300

Qy    301 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    301 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 360

Qy    361 CTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAGCACCAAGAGACCTCCACCTG 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    361 CTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAGCACCAAGAGACCTCCACCTG 420

Qy    421 CCATGGATGATTTGGATGATGATTCTGACAGTGCTGATGATGCAACAAGTAATTAACTTT 480
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    421 CCATGGATGATTTGGATGATGATTCTGACAGTGCTGATGATGCAACAAGTAATTAACTTT 480

Qy    481 CTGTGACGCAAAGCTGGGAAGGCAGCTGTGGCTATTTTCCAGTTGTTCTAGAAAGCTAGC 540
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    481 CTGTGACGCAAAGCTGGGAAGGCAGCTGTGGCTATTTTCCAGTTGTTCTAGAAAGCTAGC 540

Qy    541 GCCTAGGCCTTTGTCAGCG 559
          ||||||||||||||||||||
Db    541 GCCTAGGCCTTTGTCAGCG 559


RESULT 2
AAI58712
ID   AAI58712 standard; cDNA; 1006 BP.
XX
AC   AAI58712;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 915.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM39556.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 915; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printe
CC   specification.
XX
SQ   Sequence 1006 BP; 235 A; 244 C; 265 G; 262 T; 0 other;

  Query Match            98.3%;  Score 549.4;  DB 22;  Length 1006;
  Best Local Similarity  99.8%;  Pred. No. 8.4e-168;
  Matches  550;  Conservative    0;  Mismatches    1;  Indels    0;  Gaps    0;

Qy      1 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCA 60
          |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||||
Db    360 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCAGGTATGTGTTCA 419

Qy     61 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    420 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 479

Qy    121 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    480 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 539

Qy    181 AAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    540 AAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 599

Qy    241 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 300
```

```
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     600 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 659

Qy     301 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 360
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     660 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 719

Qy     361 CTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAGCACCAAGAGACCTCCACCTG 420
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     720 CTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAGCACCAAGAGACCTCCACCTG 779

Qy     421 CCATGGATGATTTGGATGATGATTCTGACAGTGCTGATGATGCAACAAGTAATTAACTTT 480
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     780 CCATGGATGATTTGGATGATGATTCTGACAGTGCTGATGATGCAACAAGTAATTAACTTT 839

Qy     481 CTGTGACGCAAAGCTGGGAAGGCAGCTGTGGCTATTTTCCAGTTGTTCTAGAAAGCTAGC 540
                ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     840 CTGTGACGCAAAGCTGGGAAGGCAGCTGTGGCTATTTTCCAGTTGTTCTAGAAAGCTAGC 899

Qy     541 GCCTAGGCCTT 551
                ||||||||||||
Db     900 GCCTAGGCCTT 910


RESULT 3
AAK55488
ID   AAK55488 standard; cDNA; 1859 BP.
XX
AC   AAK55488;
XX
DT   06-NOV-2001  (first entry)
XX
DE   Human immune/haematopoietic antigen encoding cDNA SEQ ID NO:548.
XX
KW   Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KW   cytostatic; gene therapy; vaccine; metastasis; ss.
XX
OS   Homo sapiens.
XX
PN   WO200157182-A2.
XX
PD   09-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US01354.
XX
PR   31-JAN-2000; 2000US-0179065.
PR   04-FEB-2000; 2000US-0180628.
PR   24-FEB-2000; 2000US-0184664.
PR   02-MAR-2000; 2000US-0186350.
PR   16-MAR-2000; 2000US-0189874.
PR   17-MAR-2000; 2000US-0190076.
PR   18-APR-2000; 2000US-0198123.
PR   19-MAY-2000; 2000US-0205515.
PR   07-JUN-2000; 2000US-0209467.
PR   28-JUN-2000; 2000US-0214886.
PR   30-JUN-2000; 2000US-0215135.
PR   07-JUL-2000; 2000US-0216647.
PR   07-JUL-2000; 2000US-0216880.
PR   11-JUL-2000; 2000US-0217487.
PR   11-JUL-2000; 2000US-0217496.
PR   14-JUL-2000; 2000US-0218290.
PR   26-JUL-2000; 2000US-0220963.
PR   26-JUL-2000; 2000US-0220964.
PR   14-AUG-2000; 2000US-0224518.
PR   14-AUG-2000; 2000US-0224519.
PR   14-AUG-2000; 2000US-0225213.
PR   14-AUG-2000; 2000US-0225214.
PR   14-AUG-2000; 2000US-0225266.
PR   14-AUG-2000; 2000US-0225267.
PR   14-AUG-2000; 2000US-0225268.
PR   14-AUG-2000; 2000US-0225270.
PR   14-AUG-2000; 2000US-0225447.
PR   14-AUG-2000; 2000US-0225757.
PR   14-AUG-2000; 2000US-0225758.
PR   14-AUG-2000; 2000US-0225759.
PR   18-AUG-2000; 2000US-0226279.
PR   22-AUG-2000; 2000US-0226681.
PR   22-AUG-2000; 2000US-0226868.
PR   22-AUG-2000; 2000US-0227182.
PR   23-AUG-2000; 2000US-0227009.
PR   30-AUG-2000; 2000US-0228924.
PR   01-SEP-2000; 2000US-0229287.
PR   01-SEP-2000; 2000US-0229343.
PR   01-SEP-2000; 2000US-0229344.
PR   01-SEP-2000; 2000US-0229345.
PR   05-SEP-2000; 2000US-0229509.
PR   05-SEP-2000; 2000US-0229513.
PR   06-SEP-2000; 2000US-0230437.
PR   06-SEP-2000; 2000US-0230438.
PR   08-SEP-2000; 2000US-0231242.
PR   08-SEP-2000; 2000US-0231243.
PR   08-SEP-2000; 2000US-0231244.
PR   08-SEP-2000; 2000US-0231413.
PR   08-SEP-2000; 2000US-0231414.
PR   08-SEP-2000; 2000US-0232080.
PR   08-SEP-2000; 2000US-0232081.
PR   12-SEP-2000; 2000US-0231968.
PR   14-SEP-2000; 2000US-0232397.
PR   14-SEP-2000; 2000US-0232398.
PR   14-SEP-2000; 2000US-0232399.
PR   14-SEP-2000; 2000US-0232400.
PR   14-SEP-2000; 2000US-0232401.
PR   14-SEP-2000; 2000US-0233063.
PR   14-SEP-2000; 2000US-0233064.
PR   14-SEP-2000; 2000US-0233065.
PR   21-SEP-2000; 2000US-0234223.
PR   21-SEP-2000; 2000US-0234274.
PR   25-SEP-2000; 2000US-0234997.
PR   25-SEP-2000; 2000US-0234998.
PR   26-SEP-2000; 2000US-0235484.
PR   27-SEP-2000; 2000US-0235834.
PR   27-SEP-2000; 2000US-0235836.
PR   29-SEP-2000; 2000US-0236327.
PR   29-SEP-2000; 2000US-0236367.
PR   29-SEP-2000; 2000US-0236368.
PR   29-SEP-2000; 2000US-0236369.
PR   29-SEP-2000; 2000US-0236370.
PR   02-OCT-2000; 2000US-0236802.
PR   02-OCT-2000; 2000US-0237037.
PR   02-OCT-2000; 2000US-0237038.
PR   02-OCT-2000; 2000US-0237039.
PR   02-OCT-2000; 2000US-0237040.
PR   13-OCT-2000; 2000US-0239935.
PR   13-OCT-2000; 2000US-0239937.
PR   20-OCT-2000; 2000US-0240960.
PR   20-OCT-2000; 2000US-0241221.
PR   20-OCT-2000; 2000US-0241785.
PR   20-OCT-2000; 2000US-0241786.
PR   20-OCT-2000; 2000US-0241787.
PR   20-OCT-2000; 2000US-0241808.
PR   20-OCT-2000; 2000US-0241809.
PR   20-OCT-2000; 2000US-0241826.
PR   01-NOV-2000; 2000US-0244617.
PR   08-NOV-2000; 2000US-0246474.
PR   08-NOV-2000; 2000US-0246475.
PR   08-NOV-2000; 2000US-0246476.
PR   08-NOV-2000; 2000US-0246477.
PR   08-NOV-2000; 2000US-0246478.
PR   08-NOV-2000; 2000US-0246523.
PR   08-NOV-2000; 2000US-0246524.
PR   08-NOV-2000; 2000US-0246525.
PR   08-NOV-2000; 2000US-0246526.
PR   08-NOV-2000; 2000US-0246527.
PR   08-NOV-2000; 2000US-0246528.
PR   08-NOV-2000; 2000US-0246532.
PR   08-NOV-2000; 2000US-0246609.
```

```
PR   08-NOV-2000; 2000US-0246610.
PR   08-NOV-2000; 2000US-0246611.
PR   08-NOV-2000; 2000US-0246613.
PR   17-NOV-2000; 2000US-0249207.
PR   17-NOV-2000; 2000US-0249208.
PR   17-NOV-2000; 2000US-0249209.
PR   17-NOV-2000; 2000US-0249210.
PR   17-NOV-2000; 2000US-0249211.
PR   17-NOV-2000; 2000US-0249212.
PR   17-NOV-2000; 2000US-0249213.
PR   17-NOV-2000; 2000US-0249214.
PR   17-NOV-2000; 2000US-0249215.
PR   17-NOV-2000; 2000US-0249216.
PR   17-NOV-2000; 2000US-0249217.
PR   17-NOV-2000; 2000US-0249218.
PR   17-NOV-2000; 2000US-0249244.
PR   17-NOV-2000; 2000US-0249245.
PR   17-NOV-2000; 2000US-0249264.
PR   17-NOV-2000; 2000US-0249265.
PR   17-NOV-2000; 2000US-0249297.
PR   17-NOV-2000; 2000US-0249299.
PR   17-NOV-2000; 2000US-0249300.
PR   01-DEC-2000; 2000US-0250160.
PR   01-DEC-2000; 2000US-0250391.
PR   05-DEC-2000; 2000US-0251030.
PR   05-DEC-2000; 2000US-0251988.
PR   05-DEC-2000; 2000US-0256719.
PR   06-DEC-2000; 2000US-0251479.
PR   08-DEC-2000; 2000US-0251856.
PR   08-DEC-2000; 2000US-0251868.
PR   08-DEC-2000; 2000US-0251869.
PR   08-DEC-2000; 2000US-0251989.
PR   08-DEC-2000; 2000US-0251990.
PR   11-DEC-2000; 2000US-0254097.
PR   05-JAN-2001; 2001US-0259678.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen CA,  Barash SC,  Ruben SM;
XX
DR   WPI; 2001-483426/52.
DR   P-PSDB; AAM82707.
XX
PT   Nucleic acids encoding human immune/hematopoietic antigen polypeptides,
PT   useful for preventing, diagnosing and/or treating cancers and
PT   metastasis -
XX
PS   Claim 1; SEQ ID NO 548; 3071pp + Sequence Listing; English.
XX
CC   AAK54951 to AAK64702 encode the human immune/haematopoietic antigen (I)
CC   amino acid sequences given in AAM82170 to AAM91921. (I) have cytostatic
CC   activity, and can be used in gene therapy and vaccine production. (I)
CC   proteins and polynucleotides may be used in the prevention, diagnosis and
CC   treatment of diseases associated with inappropriate (I) expression. For
CC   example, they may be used to treat disorders associated with decreased
CC   expression by rectifying mutations or deletions in a patient's genome
CC   that affect the activity of (I) by expressing inactive proteins or to
CC   supplement the patients own production of (I). Additionally, (I)
CC   polynucleotides may be used to produce the secreted (I), by inserting
CC   the nucleic acids into a host cell and culturing the cell to express the
CC   protein. (I) proteins and polynucleotides may be used to prevent,
CC   diagnose and treat immune/haematopoietic-related diseases, especially
CC   cancers and cancer metastases of haematopoietic-derived cells. AAK64703
CC   to AAK87694 represent human immune/haematopoietic antigen genomic
CC   sequences from the present invention. AAK54942 to AAK54950 and AAM82169
CC   represent sequences used in the exemplification of the present invention.
XX
SQ   Sequence 1859 BP; 461 A; 422 C; 567 G; 405 T; 4 other;

  Query Match             77.7%;  Score 434.6;  DB 22;  Length 1859;
  Best Local Similarity   99.3%;  Pred. No. 2.3e-130;
  Matches  434;  Conservative    2;  Mismatches    1;  Indels    0;  Gaps    0;

Qy       1 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCA 60
          ||||||||||||||:||||||||||||||||||||||||||||||| ||||||||||
Db     176 CCGCAATGGCACGGCWGCACGCCCGGACCTTGTGGTACGACAGGCCCAGGTATGTGTTCA 235

Qy      61 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 120
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     236 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 295

Qy     121 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 180
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     296 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 355

Qy     181 AAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 240
          ||:||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     356 AAKTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 415

Qy     241 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     416 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 475

Qy     301 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     476 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 535

Qy     361 CTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAGCACCAAGAGACCTCCACCTG 420
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     536 CTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAGCACCAAGAGACCTCCACCTG 595

Qy     421 CCATGGATGATTTGGAT 437
          |||||||||||||||||
Db     596 CCATGGATGATTTGGAT 612


RESULT 4
AAI58813
ID   AAI58813 standard; cDNA; 1869 BP.
XX
AC   AAI58813;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 1016.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
```

```
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM39657.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 1016; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1869 BP; 476 A; 420 C; 565 G; 408 T; 0 other;

  Query Match             77.3%;  Score 432.2;  DB 22;  Length 1869;
  Best Local Similarity   99.3%;  Pred. No. 1.4e-129;
  Matches  434;  Conservative    0;  Mismatches    3;  Indels    0;  Gaps    0;

Qy       1 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCA 60
           |||||||||||||| |||||||||||||||||||||||||||||| ||||||||||
Db     156 CCGCAATGGCACGGCTGCACGCCCGGACCTTGTGGTACGACAGGCCCAGGTATGTGTTCA 215

Qy      61 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     216 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 275

Qy     121 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     276 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 335

Qy     181 AAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 240
           || ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     336 AATTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 395

Qy     241 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 300
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     396 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 455

Qy     301 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 360
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     456 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 515

Qy     361 CTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAGCACCAAGAGACCTCCACCTG 420
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     516 CTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAGCACCAAGAGACCTCCACCTG 575

Qy     421 CCATGGATGATTTGGAT 437
           |||||||||||||||||
Db     576 CCATGGATGATTTGGAT 592


RESULT 5
AAI60498
ID   AAI60498 standard; cDNA; 1074 BP.
XX
AC   AAI60498;
XX
DT   22-OCT-2001  (first entry)
XX
DE   Human polynucleotide SEQ ID NO 4487.
XX
KW   Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW   peripheral nervous system; neuropathy; central nervous system; CNS;
KW   Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW   amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW   chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW   leukaemia; ss.
XX
OS   Homo sapiens.
XX
PN   WO200153312-A1.
XX
PD   26-JUL-2001.
XX
PF   26-DEC-2000; 2000WO-US34263.
XX
PR   21-JAN-2000; 2000US-0488725.
PR   25-APR-2000; 2000US-0552317.
PR   09-JUL-2000; 2000US-0598042.
PR   19-JUL-2000; 2000US-0620312.
PR   03-AUG-2000; 2000US-0653450.
PR   14-SEP-2000; 2000US-0662191.
PR   19-OCT-2000; 2000US-0693036.
PR   29-NOV-2000; 2000US-0727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J;
PI   Zhao QA,  Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   P-PSDB; AAM41342.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders
PT   such as central nervous system injuries -
XX
PS   Claim 1; SEQ ID NO 4487; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC   the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders.
CC   Note: The sequence data for this patent did not form part of the printed
CC   specification.
XX
SQ   Sequence 1074 BP; 264 A; 233 C; 294 G; 283 T; 0 other;

  Query Match             68.3%;  Score 381.8;  DB 22;  Length 1074;
  Best Local Similarity   99.5%;  Pred. No. 2.5e-113;
  Matches  383;  Conservative    0;  Mismatches    2;  Indels    0;  Gaps    0;

Qy       1 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCA 60
           |||||||||||||||||||||||||||||||||||||||||||||| ||||||||||
Db     428 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCAGGTATGTGTTCA 487

Qy      61 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 120
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     488 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 547

Qy     121 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 180
           ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     548 TGTTCAGCTGCAAGAATGCCGATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCA 607
```

```
Qy    181 AAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 240
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    608 AAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGA 667

Qy    241 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 300
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    668 GAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGT 727

Qy    301 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 360
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db    728 GGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGG 787

Qy    361 CTCATGTGGAACATTATGCAGAGCT 385
          ||||||||||||||||||||||| |
Db    788 CTCATGTGGAACATTATGCAGAGGT 812
```

RESULT 6
ABQ54845
ID ABQ54845 standard; cDNA; 2007 BP.
XX
AC ABQ54845;
XX
DT 22-AUG-2002 (first entry)
XX
DE Human ovarian antigen HOPKT59 cDNA, SEQ ID NO:725.
XX
KW Human; ovarian antigen; ovary; ovarian; breast; cancer; tumour;
KW ovarian cancer; breast cancer; tumour; reproductive system disorder;
KW infertility; pregnancy disorder; anovulation; polycystic ovary syndrome;
KW PCOS; ovarian cyst; dysmenorrhoea; endocrine disorder; infection;
KW inflammatory condition; immune disorder; blood disorder;
KW cardiovascular disorder; respiratory disorder; neurological disorder;
KW gastrointestinal disorder; urinary system disorder; drug screening;
KW gene therapy; chromosome mapping; forensic analysis;
KW antibody preparation; cytostatic; immunomodulatory; neuroprotective;
KW antiinflammatory; gynaecological; reproductive; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200200677-A1.
XX
PD 03-JAN-2002.
XX
PF 07-JUN-2001; 2001WO-US18569.
XX
PR 07-JUN-2000; 2000US-209467P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Birse CE, Rosen CA;
XX
DR WPI; 2002-147878/19.
DR P-PSDB; ABP41768.
XX
PT Isolated nucleic acid molecules encoding novel ovarian polypeptides,
PT useful in the prevention, treatment and diagnosis of cancer (e.g.
PT ovarian cancer), immune disorders, cardiovascular disorders and
PT neurological diseases -
XX
PS Claim 1; SEQ ID No 725; 2922pp; English.
XX
CC The invention relates to 2175 novel human ovarian antigens (ABP41054-
CC ABP43228) and to cDNAs encoding them (ABQ54131-ABQ56305), and also
CC encompasses polypeptides 90% identical and polynucleotides 95% identical
CC to the sequences of the invention. The invention additionally relates to
CC recombinant vectors and host cells comprising human ovarian antigen
CC polynucleotides, antibodies against human ovarian antigens, and the use
CC of ovarian antigen polynucleotides and polypeptides in diagnosing,
CC treating, prognosing or preventing various ovary and/or breast-related
CC disorders. Such conditions include ovarian cancer and breast cancer, and
CC metastatic tumours of ovarian or breast origin, reproductive system
CC disorders (e.g., infertility, disorders of pregnancy, anovulation,
CC polycystic ovary syndrome, ovarian cysts, and dysmenorrhoea), endocrine
CC disorders, infections (e.g., chlamydia, HIV, toxoplasmosis, and toxic
CC shock syndrome), inflammatory conditions (e.g., mastitis, oophoritis and
CC vaginitis), immune disorders (e.g., congenital and acquired
CC immunodeficiencies, autoimmune oophoritis, systemic lupus erythematosus),
CC blood-related disorders (e.g., anaemia), cardiovascular disorders,
CC respiratory disorders, neurological disorders, gastrointestinal disorders
CC and urinary system disorders. Ovarian antigen polypeptides and
CC polynucleotides may also be used in screening for compounds which
CC modulate ovarian antigen expression or activity. The polynucleotides may
CC further be used for gene therapy, chromosome mapping, in the
CC identification of individuals and in forensic analysis, and the
CC polypeptides may be used as food additives or to prepare antibodies
CC useful in disease diagnosis, drug targeting and phenotyping. The present
CC sequence represents cDNA encoding a human ovarian antigen of the
CC invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 2007 BP; 590 A; 383 C; 434 G; 600 T; 0 other;

  Query Match   18.4%; Score 103; DB 24; Length 2007;
  Best Local Similarity 54.1%; Pred. No. 1.3e-22;
  Matches 258; Conservative   0; Mismatches 210; Indels   9; Gaps   2;

```
Qy      1 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCA 60
          || |  |  ||  |||||  ||     |   |||||||||  |       ||||| ||||
Db    324 CCCCGTTCACAATGCAGCCTGCTTCTGCAAAGTGGTACGATCGAAGGGACTATGTCTTCA 383

Qy     61 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 120
          | || ||||||||||| |||||  |  |||||  | ||   | ||||  |   |    ||
Db    384 TTGAATTTTGTGTTGAAGACAGTAAGGATGTTAATGTAAATTTTGAAAAATCCAAACTTA 443

Qy    121 TGTTCAGCTGCAAGAATGCC---GATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATG 177
            ||||| ||       |     |||    |  ||   |  ||||| ||||| | | |
Db    444 CATTCAGTTGTCTCGGAGGAAGTGATAATTTTAAGCATTTAAATGAAATTGATCTTTTTC 503

Qy    178 CCAAAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTG 237
            |   |  |  | || || ||| || ||||  |  |   | | || |||   |||| |
Db    504 ACTGTATTGATCCAAATGATTCCAAGCATAAAAGAACGGACAGATCAATTTTATGTTGTT 563

Qy    238 TGAGAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAG 297
          |  ||||| |  |          | | ||||| || | || || ||       ||||
Db    564 TACGAAAAGGAGAATCTGGCCAGTCATGGCCAAGGTTAACAAAAGAAAGGGCAAAGCTTA 623

Qy    298 TGTGGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGC 357
            |||||   ||| |||||  |||| |||| ||||||||||  |||  |||    ||
Db    624 ATTGGCTTAGTGTCGACTTCAATAATTGGAAAGACTGGGAAGATGATTCAGATGAAGACA 683

Qy    358 TGGCTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAG------CACCAAGAGAC 411
          || || || | || | ||   | ||| |  |||| ||  |  |          |   |
Db    684 TGTCTAATTTTGATCGTTTCTCTGAGATGATGAACAACATGGGTGGTGATGAGGATGTAG 743

Qy    412 CTCCACCTGCCATGGATGATTTGGATGATGATTCTGACAGTGCTGATGATGCAACAA 468
          |  ||| |   | ||||     ||||||||||  |      ||||||| || ||
Db    744 ATTTACCAGAAGTAGATGGAGCAGATGATGATTCACAAGACAGTGATGATGAAAAAA 800
```

RESULT 7
AAI97619
ID AAI97619 standard; cDNA; 764 BP.
XX
AC AAI97619;
XX
DT 13-NOV-2001 (first entry)
XX
DE Human neuroblastoma expressed polynucleotide SEQ ID NO 3694.
XX
KW Human; neuroblastoma; malignancy; cancer; tumour marker; N-myc; TrkA; ss.
XX
OS Homo sapiens.

```
XX
PN   WO200166719-A1.
XX
PD   13-SEP-2001.
XX
PF   02-MAR-2001; 2001WO-JP01629.
XX
PR   07-MAR-2000; 2000JP-0159195.
XX
PA   (CHIB-) CHIBA PREFECTURE.
PA   (HISM ) HISAMITSU PHARM CO LTD.
XX
PI   Nakagawara A;
XX
DR   WPI; 2001-565584/63.
XX
PT   Nucleic acids originating in gene expressed in human neuroblastoma,
PT   useful as probe or primer in diagnosing prognosis of human
PT   neuroblastoma, malignancy and susceptibility indicator or tumour marker
PT   for anti-cancer agents -
XX
PS   Claim 1; Page 2680-2681; 2979pp; Japanese.
XX
CC   The invention relates to novel genes (AAI93926-AAI97963) expressed in
CC   human neuroblastoma. The nucleic acids are applicable as a probe or
CC   primer in diagnosing the prognosis of human neuroblastoma, malignancy and
CC   susceptibility indicators or tumour markers for anti-cancer agents. The
CC   gene information for diagnosing prognosis is related to factors similar
CC   to that for N-myc and TrkA genes.
XX
SQ   Sequence 764 BP; 229 A; 150 C; 192 G; 189 T; 4 other;

  Query Match             18.4%;  Score 102.6;  DB 22;  Length 764;
  Best Local Similarity   55.4%;  Pred. No. 1.1e-22;
  Matches  220;  Conservative    0;  Mismatches  174;  Indels    3;  Gaps    1;

Qy       1 CCGCAATGGCACGGCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCA 60
Db     207 CCCCGTTCACAATGCAGCCTGCTTCTGCAAAGTGGTACGATCGAAGGGACTATGTCTTCA 266

Qy      61 TGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTG 120
Db     267 TTGAATTTTGTGTTGAAGACAGTAAGGATGTTAATGTAAATTTTGAAAAATCCAAACTTA 326

Qy     121 TGTTCAGCTGCAAGAATGCC---GATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATG 177
Db     327 CATTCAGTTGTCTCGGAGGAAGTGATAATTTTAAGCATTTAAATGAAATTGATCTTTTTC 386

Qy     178 CCAAAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTG 237
Db     387 ACTGTATTGATCCAAATGATTCCAAGCATAAAAGAACGGACAGATCAATTTTATGTTGTT 446

Qy     238 TGAGAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAG 297
Db     447 TACGAAAAGGAGAATCTGGCCAGTCATGGCCAGGGTTAACAAAAGAAAGGGCAAAGCTTA 506

Qy     298 TGTGGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGC 357
Db     507 ATTGGCTTAATGTCGACTTCAATAATTGGAAAGACTGGGAAGATGATTCAGATGAAGACA 566

Qy     358 TGGCTCATGTGGAACATTATGCAGAGCTTTTGAAGAA 394
Db     567 TGTCTAATTTTGATCGTTTCTCTGAGATGATGAACAA 603


RESULT 8
AAH43100
ID   AAH43100 standard; DNA; 483 BP.
XX
AC   AAH43100;
XX
DT   15-OCT-2001  (first entry)
XX
DE   Nucleotide sequence of a human prostaglandin E1 (PGE1) synthase.
XX
KW   Human; prostaglandin E1 synthase; PGE1 synthase; arachidonic acid;
KW   inflammation; ss.
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   CDS             1..483
FT                   /*tag= a
FT                   /product= "prostaglandin E1 (PGE1) synthase"
XX
PN   WO200157225-A1.
XX
PD   09-AUG-2001.
XX
PF   25-AUG-2000; 2000WO-JP05758.
XX
PR   03-FEB-2000; 2000JP-0032704.
XX
PA   (CHUS ) CHUGAI SEIYAKU KK.
PA   (KUDO/) KUDO I.
XX
PI   Kudo I,  Murakami M,  Ohishi S;
XX
DR   WPI; 2001-483439/52.
DR   P-PSDB; AAG63379.
XX
PT   PGES-1 protein and encoded gene with PGE2 synthase activity, useful in
PT   screening efficient PGE2 synthase inhibitors as antiinflammatory agents
PT   -
XX
PS   Disclosure; Fig 5; 54pp; Japanese.
XX
CC   The present sequence encodes a human prostaglandin E1 (PGE1) synthase.
CC   The protein synthesizes PGE2 from arachidonic acid in consort with COX.
CC   The PGE2 synthase protein and gene are useful in screening for efficient
CC   PGE2 synthase inhibitors. These inhibitors are useful as
CC   anti-inflammatory agents.
XX
SQ   Sequence 483 BP; 166 A; 63 C; 114 G; 140 T; 0 other;

  Query Match             18.1%;  Score 101.2;  DB 22;  Length 483;
  Best Local Similarity   54.3%;  Pred. No. 2.3e-22;
  Matches  252;  Conservative    0;  Mismatches  203;  Indels    9;  Gaps    2;

Qy      14 GCAGCACGCCCGGACCTTGTGGTACGACAGGCCCATGTATGTGTTCATGGAGTTTTGTGT 73
Db       3 GCAGCCTGCTTCTGCAAAGTGGTACGATCGAAGGGACTATGTCTTCATTGAATTTTGTGT 62

Qy      74 TGAGGACAGCACCGATGTCCACGTGCTTATTGAGGATCACCGCATTGTGTTCAGCTGCAA 133
Db      63 TGAAGACAGTAAGGATGTTAATGTAAATTTTGAAAAATCCAAACTTACATTCAGTTGTCT 122

Qy     134 GAATGCC---GATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCAAAGTGAACTC 190
Db     123 CGGAGGAAGTGATAATTTTAAGCATTTAAATGAAATTGATCTTTTTCACTGTATTGATCC 182

Qy     191 CAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGAGAAAATGGAA 250
Db     183 AAATGATTCCAAGCATAAAAGAACGGACAGATCAATTTTATGTTGTTTACGAAAAGGAGA 242

Qy     251 GGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGTGGCTGTCTGT 310
Db     243 ATCTGGCCAGTCATGGCCAAGGTTAACAAAAGAAAGGGCAAAGCTTAATTGGCTTAGTGT 302

Qy     311 GGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGGCTCATGTGGA 370
Db     303 CGACTTCAATAATTGGAAAGACTGGGAAGATGATTCAGATGAAGACATGTCTAATTTTGA 362

Qy     371 ACATTATGCAGAGCTTTTGAAGAAGGTCAG------CACCAAGAGACCTCCACCTGCCAT 424
Db     363 TCGTTTCTCTGAGATGATGAACAACATGGGTGGTGATGAGGATGTAGATTTACCAGAAGT 422
```

```
Qy     425 GGATGATTTGGATGATGATTCTGACAGTGCTGATGATGCAACAA 468
           ||||     ||||||||||| |      |||||||| || ||
Db     423 AGATGGAGCAGATGATGATTCACAAGACAGTGATGATGAAAAAA 466
```

RESULT 9
ABQ58935
ID ABQ58935 standard; cDNA; 569 BP.
XX
AC ABQ58935;
XX
DT 02-AUG-2002 (first entry)
XX
DE Human colon cancer related nucleotide sequence SEQ ID NO:2630.
XX
KW Human; colon cancer; cancer; tissue profiling; forensic; mapping;
KW genetic analysis; diagnostic; antisense therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200229086-A2.
XX
PD 11-APR-2002.
XX
PF 02-OCT-2001; 2001WO-US30732.
XX
PR 02-OCT-2000; 2000US-237271P.
XX
PA (FARB) BAYER CORP.
XX
PI Burgess C, Astle JH, Carroll E, Catino TJ, Dwivedi P, Molino GA;
PI Thiaglingam A, Lewis ME;
XX
DR WPI; 2002-426115/45.
XX
PT New isolated nucleic acid that is differentially expressed in cancer
PT tissues useful for determining the presence of colon cancer in a cell
PT or tissue type, and in antisense therapy -
XX
PS Claim 1; Fig 1; 796pp; English.
XX
CC ABQ56306 to ABQ60787 represent isolated nucleic acids (I) differentially
CC expressed in cancer tissues. ABB78993 to ABB79004 represent proteins
CC encoded by the ABQ60776 to ABQ60787 nucleic acid sequences. (I) can be
CC used in antisense therapy. An antibody immunoreactive with a polypeptide
CC encoded by (I) is useful for detecting cancer in a patient sample, and
CC for detecting the presence or absence of a polynucleotide encoded by a
CC nucleic acid which hybridises to (I) in a cell. A probe/primer derived
CC from (I) can be used for determining the presence of a nucleic acid which
CC hybridises to (I), and for determining the phenotype of cells in a sample
CC of cells from a patient. (I) is useful for determining the presence of
CC colon cancer in a cell or tissue type, for determining the presence or
CC state of other type of cancer, in antisense therapy, to generate
CC macroarrays on a solid surface, to identify a chromosome on which the
CC corresponding gene resides, and in tissue profiling, forensics, genetic
CC analysis, mapping and diagnostic applications. (I) can be used to raise
CC antibodies, and to screen for peptide analogues and antagonists.
XX
SQ Sequence 569 BP; 199 A; 74 C; 127 G; 166 T; 3 other;

  Query Match   16.9%; Score 94.2; DB 24; Length 569;
  Best Local Similarity 56.5%; Pred. No. 4.8e-20;
  Matches 196; Conservative   0; Mismatches 148; Indels   3; Gaps   1;

```
Qy      51 TATGTGTTCATGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGAT 110
           ||||| ||||| || |||||||||||| ||||| |  |||||  | ||   | ||||  |
Db      15 TATGTCTTCATTGAATTTTGTGTTGAAGACAGTAAGGATGTTAATGTAAATTTTGAAAAA 74

Qy     111 CACCGCATTGTGTTCAGCTGCAAGAATGCC---GATGGAGTGGAGTTGTACAATGAGATT 167
             |    ||   ||||| ||       |     |||   |  ||   |  ||||| |||
Db      75 TCCAAACTTACATTCAGTTGTCTCGGAGGAAGTGATAATTTTAAGCATTTAAATGAAATT 134

Qy     168 GAGTTCTATGCCAAAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATT 227
           ||  | | |  |     |  |  | || || ||| || ||||  |  |   | | || |||
Db     135 GATCTTTTTCACTGTATTGATCCAAATGATTCCAAGCATAAAAGAACGGACAGATCAATT 194

Qy     228 ACTTGTTTTGTGAGAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGAT 287
           |||| | |  ||||| |  |          | | |||||  || | || || ||
Db     195 TTATGTTGTTTACGAAAAGGAGAATCTGGCCAGTCATGGCCAAGGTTAACAAAAGAAAGG 254

Qy     288 ATCAAGCCAGTGTGGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAA 347
           ||||     |||||   ||| ||||| |||| |||| ||||||||||  |||  |
Db     255 GCAAAGCTTAATTGGCTTAGTGTCGACTTCAATAATTGGAAAGACTGGGAAGATGATTCA 314

Qy     348 GAGATGGAGCTGGCTCATGTGGAACATTATGCAGAGCTTTTGAAGAA 394
           ||    ||  || || || | || | ||   | ||| |  |||| ||
Db     315 GATGAAGACATGTCTAATTTTGATCGTTTCTCTGAGATGATGAACAA 361

RESULT 10
ABQ57521
ID  ABQ57521 standard; cDNA; 664 BP.
XX
AC  ABQ57521;
XX
DT  02-AUG-2002  (first entry)
XX
DE  Human colon cancer related nucleotide sequence SEQ ID NO:1216.
XX
KW  Human; colon cancer; cancer; tissue profiling; forensic; mapping;
KW  genetic analysis; diagnostic; antisense therapy; gene; ss.
XX
OS  Homo sapiens.
XX
PN  WO200229086-A2.
XX
PD  11-APR-2002.
XX
PF  02-OCT-2001; 2001WO-US30732.
XX
PR  02-OCT-2000; 2000US-237271P.
XX
PA  (FARB ) BAYER CORP.
XX
PI  Burgess C,  Astle JH,  Carroll E,  Catino TJ,  Dwivedi P,  Molino GA;
PI  Thiaglingam A,  Lewis ME;
XX
DR  WPI; 2002-426115/45.
XX
PT  New isolated nucleic acid that is differentially expressed in cancer
PT  tissues useful for determining the presence of colon cancer in a cell
PT  or tissue type, and in antisense therapy  -
XX
PS  Claim 1; Fig 1; 796pp; English.
XX
CC  ABQ56306 to ABQ60787 represent isolated nucleic acids (I) differentially
CC  expressed in cancer tissues. ABB78993 to ABB79004 represent proteins
CC  encoded by the ABQ60776 to ABQ60787 nucleic acid sequences. (I) can be
CC  used in antisense therapy. An antibody immunoreactive with a polypeptide
CC  encoded by (I) is useful for detecting cancer in a patient sample, and
CC  for detecting the presence or absence of a polynucleotide encoded by a
CC  nucleic acid which hybridises to (I) in a cell. A probe/primer derived
CC  from (I) can be used for determining the presence of a nucleic acid which
CC  hybridises to (I), and for determining the phenotype of cells in a sample
CC  of cells from a patient. (I) is useful for determining the presence of
CC  colon cancer in a cell or tissue type, for determining the presence or
CC  state of other type of cancer, in antisense therapy, to generate
CC  macroarrays on a solid surface, to identify a chromosome on which the
CC  corresponding gene resides, and in tissue profiling, forensics, genetic
CC  analysis, mapping and diagnostic applications. (I) can be used to raise
CC  antibodies, and to screen for peptide analogues and antagonists.
XX
SQ  Sequence 664 BP; 208 A; 94 C; 151 G; 206 T; 5 other;

  Query Match            16.9%;  Score 94.2;  DB 24;  Length 664;
```

```
  Best Local Similarity   55.6%;  Pred. No. 5.3e-20;
  Matches  202;  Conservative    0;  Mismatches  158;  Indels    3;  Gaps    1;

Qy      35 GTACGACAGGCCCATGTATGTGTTCATGGAGTTTTGTGTTGAGGACAGCACCGATGTCCA 94
           | ||||  |       ||||| ||||| || ||||||||||| ||||| |  |||||  |
Db       1 GGACGATCGAAGGGACTATGTCTTCATTGAATTTTGTGTTGAAGACAGTAAGGATGTTAA 60

Qy      95 CGTGCTTATTGAGGATCACCGCATTGTGTTCAGCTGCAAGAATGCC---GATGGAGTGGA 151
           ||   | ||||  |   |    ||   ||||| ||       |     |||    |  |
Db      61 TGTAAATTTTGAAAAATCCAAACTTACATTCAGTTGTCTCGGAGGAAGTGATAATTTTAA 120

Qy     152 GTTGTACAATGAGATTGAGTTCTATGCCAAAGTGAACTCCAAGGACTCCCAGGATAAGCG 211
           |   |  ||||| |||||  | | |  |   |  | || || ||| || ||||  |
Db     121 GCATTTAAATGAAATTGATCTTTTTCACTGTATTGATCCAAATGATTCCAAGCATAAAAG 180

Qy     212 CTCTTCCCGCTCTATTACTTGTTTTGTGAGAAAATGGAAGGAAAAGGTGGCCTGGCCGCG 271
           |   | | || |||   |||| | |  ||||| |  |        | | |||||  |
Db     181 AACGGACAGATCAATTTTATGTTGTTTACGAAAAGGAGAATCTGGCCAGTCATGGCCAAG 240

Qy     272 GCTTACCAAGGAGGATATCAAGCCAGTGTGGCTGTCTGTGGACTTTGATAACTGGAGAGA 331
           | | || || ||       ||||     |||||   ||| |||||  |||| |||| |||
Db     241 GTTAACAAAAGAAAGGGCAAAGCTTAATTGGCTTAGTGTCGACTTCAATAATTGGAAAGA 300

Qy     332 CTGGGAAGGGGATGAAGAGATGGAGCTGGCTCATGTGGAACATTATGCAGAGCTTTTGAA 391
           ||||||||  |||  |||    ||  || || || | || | ||   | ||| |  ||||
Db     301 CTGGGAAGATGATTCAGATGAAGACATGTCTAATTTTGATCGTTTCTCTGAGATGATGAA 360

Qy     392 GAA 394
           ||
Db     361 CAA 363


RESULT 11
ABL37927
ID   ABL37927 standard; cDNA; 570 BP.
XX
AC   ABL37927;
XX
DT   08-APR-2002  (first entry)
XX
DE   Human colon tumour antigen polynucleotide SEQ ID NO:1516.
XX
KW   Human; colon cancer; colon tumour antigen; cytostatic; vaccine;
KW   colon tumour metastatic antigen; diagnosis; gene; ss.
XX
OS   Homo sapiens.
XX
PN   WO200196388-A2.
XX
PD   20-DEC-2001.
XX
PF   08-JUN-2001; 2001WO-US18557.
XX
PR   09-JUN-2000; 2000US-210899P.
PR   20-FEB-2001; 2001US-270216P.
XX
PA   (CORI-) CORIXA CORP.
XX
PI   Jiang Y,  Harlocker SL,  Secrist H;
XX
DR   WPI; 2002-114514/15.
XX
PT   Novel isolated colon tumor polynucleotide differentially expressed in
PT   colon tumor or colon metastatic tumor and polypeptides encoded by them,
PT   useful for inhibiting development of cancer in patient -
XX
PS   Claim 1; SEQ ID 1516; 105pp; English.
XX
CC   ABL36412 to ABL38645 represent human colon tumour antigen cDNA clones (I)
CC   which were isolated from human colon tumour and colon metastatic tumour
CC   cDNA libraries. (I) have cytostatic activity and can be used in vaccine
CC   production. (I) can be used for stimulating and/or expanding T cells
CC   specific for a tumour protein on contact with the T cells. They are also
CC   useful for inhibiting the development of cancer in a patient. (I) can be
CC   used as probes or primers for nucleic acid hybridisation, for preparing
CC   mutant species primers, or primers for use in genetic constructions. (I)
CC   can be used in the diagnosis of a colon tumour.
XX
SQ   Sequence 570 BP; 199 A; 73 C; 128 G; 167 T; 3 other;

  Query Match           16.6%;  Score 93;  DB 24;  Length 570;
  Best Local Similarity   54.6%;  Pred. No. 1.2e-19;
  Matches  233;  Conservative    0;  Mismatches  185;  Indels    9;  Gaps    2;

Qy      51 TATGTGTTCATGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGAT 110
           || || ||||| || |||||||||||| ||||| |  |||||  | ||   | ||||  |
Db      15 TACGTCTTCATTGAATTTTGTGTTGAAGACAGTAAGGATGTTAATGTAAATTTTGAAAAA 74

Qy     111 CACCGCATTGTGTTCAGCTGCAAGAATG---CCGATGGAGTGGAGTTGTACAATGAGATT 167
           |    ||  ||||| ||       |     |||    |  ||   |  ||||| |||
Db      75 TCCAAACTTACATTCAGTTGTCTCGGAGGAAGTGATAATTTTAAGCATTTAAATGAAATT 134

Qy     168 GAGTTCTATGCCAAAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATT 227
           ||  | | |  |    |  |  | || || ||| || ||||  |  |   | | || |||
Db     135 GATCTTTTTCACTGTATTGATCCAAATGATTCCAAGCATAAAAGAACGGACAGATCAATT 194

Qy     228 ACTTGTTTTGTGAGAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGAT 287
           |||| | |  ||||| |  |         | | |||||  || | || || ||
Db     195 TTATGTTGTTTACGAAAAGGAGAATCTGGCCAGTCATGGCCAAGGTTAACAAAAGAAAGG 254

Qy     288 ATCAAGCCAGTGTGGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAA 347
           ||||     |||||   ||| |||||  |||| |||| ||||||||||  |||  |
Db     255 GCAAAGCTTAATTGGCTTAGTGTCGACTTCAATAATTGGAAAGACTGGGAAGATGATTCA 314

Qy     348 GAGATGGAGCTGGCTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAG------C 401
           ||    ||  || || || | || | ||   | ||| |  |||| ||  |  |
Db     315 GATGAAGACATGTCTAATTTTGATCGTTTCTCTGAGATGATGAACAACATGGGTGGTGAT 374

Qy     402 ACCAAGAGACCTCCACCTGCCATGGATGATTTGGATGATGATTCTGACAGTGCTGATGAT 461
           |   |  | ||| |   | ||||     ||||||||||  |      |||||||
Db     375 GAGGATGTAGATTTACCAGAAGTAGATGGAGCAGATGATGATTCACAAGACAGTGATGAT 434

Qy     462 GCAACAA 468
           | || ||
Db     435 GAAAAAA 441


RESULT 12
ABQ59145
ID   ABQ59145 standard; cDNA; 575 BP.
XX
AC   ABQ59145;
XX
DT   02-AUG-2002  (first entry)
XX
DE   Human colon cancer related nucleotide sequence SEQ ID NO:2840.
XX
KW   Human; colon cancer; cancer; tissue profiling; forensic; mapping;
KW   genetic analysis; diagnostic; antisense therapy; gene; ss.
XX
OS   Homo sapiens.
XX
PN   WO200229086-A2.
XX
PD   11-APR-2002.
XX
PF   02-OCT-2001; 2001WO-US30732.
XX
PR   02-OCT-2000; 2000US-237271P.
XX
PA   (FARB ) BAYER CORP.
XX
PI   Burgess C,  Astle JH,  Carroll E,  Catino TJ,  Dwivedi P,  Molino GA;
PI   Thiaglingam A,  Lewis ME;
XX
DR   WPI; 2002-426115/45.
```

XX
PT New isolated nucleic acid that is differentially expressed in cancer
PT tissues useful for determining the presence of colon cancer in a cell
PT or tissue type, and in antisense therapy -
XX
PS Claim 1; Fig 1; 796pp; English.
XX
CC ABQ56306 to ABQ60787 represent isolated nucleic acids (I) differentially
CC expressed in cancer tissues. ABB78993 to ABB79004 represent proteins
CC encoded by the ABQ60776 to ABQ60787 nucleic acid sequences. (I) can be
CC used in antisense therapy. An antibody immunoreactive with a polypeptide
CC encoded by (I) is useful for detecting cancer in a patient sample, and
CC for detecting the presence or absence of a polynucleotide encoded by a
CC nucleic acid which hybridises to (I) in a cell. A probe/primer derived
CC from (I) can be used for determining the presence of a nucleic acid which
CC hybridises to (I), and for determining the phenotype of cells in a sample
CC of cells from a patient. (I) is useful for determining the presence of
CC colon cancer in a cell or tissue type, for determining the presence or
CC state of other type of cancer, in antisense therapy, to generate
CC macroarrays on a solid surface, to identify a chromosome on which the
CC corresponding gene resides, and in tissue profiling, forensics, genetic
CC analysis, mapping and diagnostic applications. (I) can be used to raise
CC antibodies, and to screen for peptide analogues and antagonists.
XX
SQ Sequence 575 BP; 186 A; 72 C; 116 G; 179 T; 22 other;

Query Match 15.1%; Score 84.4; DB 24; Length 575;
Best Local Similarity 56.5%; Pred. No. 7.4e-17;
Matches 196; Conservative 0; Mismatches 147; Indels 4; Gaps 2;

```
Qy      51 TATGTGTTCATGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGAT 110
           ||||| ||||| || |||||||||||| ||||| |  |||||  | ||   | ||||  |
Db      15 TATGTCTTCATTGAATTTTGTGTTGAAGACAGTAAGGATGTTAATGTAAATTTTGAAAAA 74

Qy     111 CACCGCATTGTGTTCAGCTGCAAGAATGCC---GATGGAGTGGAGTTGTACAATGAGATT 167
             |    ||   ||||| ||       |     |||    |  ||   |  ||||| |||
Db      75 TCCAAACTTACATTCAGTTGTCTCGGAGGAAGTGATAATTTTAAGCATTTAAATGAAATT 134

Qy     168 GAGTTCTATGCCAAAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATT 227
           ||  | | |  |    |  |  | || || ||| || ||||  |  |   | | || |||
Db     135 GATCTTTTTCACTGTATTGATCCAAATGATTCCAAGCATAAAAGAACGGACAGATCAATT 194

Qy     228 ACTTGTTTTGTGAGAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGAT 287
             |||| | |  ||||| |  |          | | |||||   | | || || ||  |
Db     195 TTATGTTGTTTACGAAAAGGAGAATCTGGCCAGTCATGGCCAANGTTAACAAAAGA-AAG 253

Qy     288 ATCAAGCCAGTGTGGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAA 347
             ||||     |||||   ||| |||||  |||| |||| ||||||||||  |||  |
Db     254 GCAAAGCTTAATTGGCTTAGTGTCGACTTCAATAATTGGAAAGACTGGGAAGATGATTCA 313

Qy     348 GAGATGGAGCTGGCTCATGTGGAACATTATGCAGAGCTTTTGAAGAA 394
           ||    ||  || || || | || | ||   | ||| |  |||| ||
Db     314 GATGAAGACATGTCTAATTTTGATCGTTTCTCTGAGATGATGAACAA 360
```

RESULT 13
ABQ58126
ID ABQ58126 standard; cDNA; 561 BP.
XX
AC ABQ58126;
XX
DT 02-AUG-2002 (first entry)
XX
DE Human colon cancer related nucleotide sequence SEQ ID NO:1821.
XX
KW Human; colon cancer; cancer; tissue profiling; forensic; mapping;
KW genetic analysis; diagnostic; antisense therapy; gene; ss.
XX
OS Homo sapiens.
XX
PN WO200229086-A2.
XX
PD 11-APR-2002.
XX
PF 02-OCT-2001; 2001WO-US30732.
XX
PR 02-OCT-2000; 2000US-237271P.
XX
PA (FARB) BAYER CORP.
XX
PI Burgess C, Astle JH, Carroll E, Catino TJ, Dwivedi P, Molino GA;
PI Thiaglingam A, Lewis ME;
XX
DR WPI; 2002-426115/45.
XX
PT New isolated nucleic acid that is differentially expressed in cancer
PT tissues useful for determining the presence of colon cancer in a cell
PT or tissue type, and in antisense therapy -
XX
PS Claim 1; Fig 1; 796pp; English.
XX
CC ABQ56306 to ABQ60787 represent isolated nucleic acids (I) differentially
CC expressed in cancer tissues. ABB78993 to ABB79004 represent proteins
CC encoded by the ABQ60776 to ABQ60787 nucleic acid sequences. (I) can be
CC used in antisense therapy. An antibody immunoreactive with a polypeptide
CC encoded by (I) is useful for detecting cancer in a patient sample, and
CC for detecting the presence or absence of a polynucleotide encoded by a
CC nucleic acid which hybridises to (I) in a cell. A probe/primer derived
CC from (I) can be used for determining the presence of a nucleic acid which
CC hybridises to (I), and for determining the phenotype of cells in a sample
CC of cells from a patient. (I) is useful for determining the presence of
CC colon cancer in a cell or tissue type, for determining the presence or
CC state of other type of cancer, in antisense therapy, to generate
CC macroarrays on a solid surface, to identify a chromosome on which the
CC corresponding gene resides, and in tissue profiling, forensics, genetic
CC analysis, mapping and diagnostic applications. (I) can be used to raise
CC antibodies, and to screen for peptide analogues and antagonists.
XX
SQ Sequence 561 BP; 192 A; 73 C; 128 G; 167 T; 1 other;

Query Match 14.8%; Score 82.6; DB 24; Length 561;
Best Local Similarity 54.6%; Pred. No. 2.8e-16;
Matches 233; Conservative 0; Mismatches 184; Indels 10; Gaps 3;

```
Qy      51 TATGTGTTCATGGAGTTTTGTGTTGAGGACAGCACCGATGTCCACGTGCTTATTGAGGAT 110
           ||||| ||||| || |||||||||||| ||||| |  |||||  | ||   | ||||  |
Db      14 TATGTCTTCATTGAATTTTGTGTTGAAGACAGTAAGGATGTTAATGTAAATTTTGAAAAA 73

Qy     111 CACCGCATTGTGTTCAGCTGCAAGAATGCC---GATGGAGTGGAGTTGTACAATGAGATT 167
             |    ||   ||||| ||       |     |||    |  ||   |  ||||| |||
Db      74 TCCAAACTTACATTCAGTTGTCTCGGAGGAAGTGATAATTTTAAGCATTTAAATGAAATT 133

Qy     168 GAGTTCTATGCCAAAGTGAACTCCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATT 227
           ||  | | |  |    |  |  | || || ||| || ||||  |  |   | | || |||
Db     134 GATCTTTTTCACTGTATTGATCCAAATGATTCCAAGCATAAAAGAACGGACAGATCAATT 193

Qy     228 ACTTGTTTTGTGAGAAAATGGAAGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGAT 287
             |||| | |  ||||| |  |          | | |||||  || | || || ||
Db     194 TTATGTTGTTTACGAAAAGGAGAATCTGGCCAGTCATGGCCAAGGTTAACAAAAGAAAGG 253

Qy     288 ATCAAGCCAGTGTGGCTGTCTGTGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAA 347
             ||||     |||||   ||| | |||  |||| |||| ||||||||||  |||  |
Db     254 GCAAAGCTTAATTGGCTTAGTGTCG-CTTCAATAATTGGAAAGACTGGGAAGATGATTCA 312

Qy     348 GAGATGGAGCTGGCTCATGTGGAACATTATGCAGAGCTTTTGAAGAAGGTCAG------C 401
           ||    ||  || || || | || | ||   | ||| |  |||| ||  |   |
Db     313 GATGAAGACATGTCTAATTTTGATCGTTTCTCTGAGATGATGAACAACATGGGTGGTGAT 372

Qy     402 ACCAAGAGACCTCCACCTGCCATGGATGATTTGGATGATGATTCTGACAGTGCTGATGAT 461
             |   |  |  ||| |   | ||||     ||||||||||  |      |||||||
Db     373 GAGGATGTAGATTTACCAGAAGTAGATGGAGCAGATGATGATTCACAAGACAGTGATGAT 432

Qy     462 GCAACAA 468
           | || ||
Db     433 GAAAAAA 439
```

RESULT 14
ABK09599/c
ID ABK09599 standard; cDNA; 473 BP.
XX
AC ABK09599;
XX
DT 14-MAR-2002 (first entry)
XX
DE Human ovarian tumour protein encoding cDNA #136.
XX
KW Human; ovarian tumour protein; cancer; cytostatic; immunostimulant; ss;
KW gene therapy; CD4+ T cell; CD8+ T cell; PCR primer.
XX
OS Homo sapiens.
XX
PN WO200190154-A2.
XX
PD 29-NOV-2001.
XX
PF 23-MAY-2001; 2001WO-US16895.
XX
PR 24-MAY-2000; 2000US-207107P.
PR 13-JUN-2000; 2000US-211457P.
PR 21-JUN-2000; 2000US-213673P.
PR 03-AUG-2000; 2000US-223288P.
PR 01-MAR-2001; 2001US-272790P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Xu J, Mitcham JL, Harlocker SL, Dillon DC, Secrist H, Lodes MJ;
PI Algate PA, Fling SP, Mannion J, Benson DR, Carter D;
XX
DR WPI; 2002-097641/13.
XX
PT New isolated polynucleotide encoding polypeptide comprising portion of
PT ovarian tumour protein, useful for detection, diagnosis and therapy of
PT human ovarian cancer -
XX
PS Claim 1; Page 169; 285pp; English.
XX
CC The invention relates to an isolated polynucleotide encoding a
CC polypeptide comprising a portion of an ovarian tumour protein. The
CC sequences of the invention are useful for stimulating an immune response
CC and for treating ovarian cancer in a patient. An antigen presenting cell
CC that expresses the sequences is useful for treating ovarian cancer by
CC incubating CD4+ and/or CD8+ T cells isolated from a patient. The T cells
CC can then be proliferated and administered to the patient to inhibit the
CC development of cancer. The DNA sequences are useful as probes or primers
CC for nucleic acid hybridisation, to direct expression of a polypeptide in
CC appropriate host cells. Detecting the presence of a cancer in a patient
CC involves obtaining a biological sample from the patient, contacting the
CC biological sample with an agent that binds to the protein, detecting the
CC amount of protein that binds to the agent, comparing the amount of
CC protein to a predetermined cut-off value and determining the presence of
CC cancer. Sequences ABK09464-ABK09802 represent PCR primers and cDNA
CC molecules encoding ovarian tumour proteins of the invention.
XX
SQ Sequence 473 BP; 138 A; 105 C; 60 G; 170 T; 0 other;

Query Match 13.5%; Score 75.2; DB 24; Length 473;
Best Local Similarity 53.9%; Pred. No. 6.5e-14;
Matches 180; Conservative 0; Mismatches 148; Indels 6; Gaps 1;

```
Qy    141 GATGGAGTGGAGTTGTACAATGAGATTGAGTTCTATGCCAAAGTGAACTCCAAGGACTCC 200
          |||    |  ||   |  ||||| |||||  | | |  |    |  |  | || || |||
Db    418 GATAATTTTAAGCATTTAAATGAAATTGATCTTTTTCACTGTATTGATCCAAATGATTCC 359

Qy    201 CAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGAGAAAATGGAAGGAAAAGGTG 260
          || ||||  |  |   | | || |||   |||| | |  ||||| |  |         |
Db    358 AAGCATAAAAGAACGGACAGATCAATTTTATGTTGTTTACGAAAAGGAGAATCTGGCCAG 299

Qy    261 GCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGTGGCTGTCTGTGGACTTTGAT 320
```

```
          | |||||  || | || || ||       ||||    |||||  ||| |||||  ||
Db    298 TCATGGCCAAGGTTAACAAAAGAAAGGGCAAAGCTTAATTGGCTTAGTGTCGACTTCAAT 239

Qy    321 AACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGGCTCATGTGGAACATTATGCA 380
          || |||| ||||||||||||  |||  |||    ||  || || || | || | ||   |
Db    238 AATTGGAAAGACTGGGAAGATGATTCAGATGAAGACATGTCTAATTTTGATCGTTTCTCT 179

Qy    381 GAGCTTTTGAAGAAGGTCAG------CACCAAGAGACCTCCACCTGCCATGGATGATTTG 434
          ||| |  |||| ||  |  |           |   |  |  ||| |   | ||||
Db    178 GAGATGATGAACAACATGGGTGGTGATGAGGATGTAGATTTACCAGAAGTAGATGGAGCA 119

Qy    435 GATGATGATTCTGACAGTGCTGATGATGCAACAA 468
          ||||||||||  |      |||||||| || ||
Db    118 GATGATGATTCACAAGACAGTGATGATGAAAAAA 85
```

RESULT 15
ABN88218/c
ID ABN88218 standard; cDNA; 471 BP.
XX
AC ABN88218;
XX
DT 13-AUG-2002 (first entry)
XX
DE Human colon cancer related cDNA clone 63084.1 SEQ ID NO:14.
XX
KW Human; colon cancer; colon tumour; gene; cytostatic; immune response;
KW gene therapy; vaccine; ss.
XX
OS Homo sapiens.
XX
PN WO200241763-A2.
XX
PD 30-MAY-2002.
XX
PF 18-OCT-2001; 2001WO-US50718.
XX
PR 20-OCT-2000; 2000US-242321P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Jiang Y;
XX
DR WPI; 2002-471685/50.
XX
PT New colon cancer polynucleotide and polypeptide, useful for detecting
PT the presence of cancer in a patient, and in pharmaceutical
PT compositions, e.g. vaccines, for treating colon cancer -
XX
PS Claim 1; Page 113; 125pp; English.
XX
CC ABN88205 to ABN88262 represents human colon cancer related cDNA clone
CC polynucleotide sequences (I). (I) have cytostatic activity, can be
CC used as immune response stimulators, and in gene therapy and vaccine
CC production. (I) and the proteins encoded by them (II) can be used for
CC detecting the presence of cancer in a patient, by obtaining a biological
CC sample from the patient, contacting the biological sample with a binding
CC agent that binds to (II), detecting in the sample an amount of (II) that
CC binds to the binding agent and comparing the amount of (II) to a
CC predetermined cut-off value, and so determining the presence of a cancer
CC in the patient. (I) and (II) are useful in pharmaceutical compositions,
CC e.g. vaccines.
XX
SQ Sequence 471 BP; 134 A; 107 C; 64 G; 161 T; 5 other;

Query Match 11.7%; Score 65.4; DB 24; Length 471;
Best Local Similarity 54.0%; Pred. No. 9.9e-11;
Matches 154; Conservative 0; Mismatches 125; Indels 6; Gaps 1;

```
Qy    190 CCAAGGACTCCCAGGATAAGCGCTCTTCCCGCTCTATTACTTGTTTTGTGAGAAAATGGA 249
          | || || ||| || ||||  |  |   | | || |||   |||| |     |||| |
Db    471 CAAATGATTCCAAGCATAAAAGANCGGACAGATCAATTTTATGTTGTAAANNAAAAGGAG 412
```

```
Qy     250 AGGAAAAGGTGGCCTGGCCGCGGCTTACCAAGGAGGATATCAAGCCAGTGTGGCTGTCTG 309
Db     411 NATCTGGCCAGTCATGGCCAAGGTTAACAAAAGAAAGGGCAAAGCTTAATTGGCTTAGTG 352

Qy     310 TGGACTTTGATAACTGGAGAGACTGGGAAGGGGATGAAGAGATGGAGCTGGCTCATGTGG 369
Db     351 TCGACTTCAATAATTGGAAAGACTGGGAAGATGATTCAGATGAAGACATGTCTAATTTTG 292

Qy     370 AACATTATGCAGAGCTTTTGAAGAAGGTCAG------CACCAAGAGACCTCCACCTGCCA 423
Db     291 ATCGTTTCTCTGAGATGATGAACAACATGGGTGGTGATGAGGATGTAGATTTACCAGAAG 232

Qy     424 TGGATGATTTGGATGATGATTCTGACAGTGCTGATGATGCAACAA 468
Db     231 TAGATGGAGCAGATGATGATTCACAAGACAGTGATGATGAAAAAA 187
```

Search completed: March 20, 2003, 02:46:12
Job time : 244 secs